5 ASX shares I'm avoiding this week

There's warning bells ahead for these stocks.

| More on:
A business woman looks unhappy while she flies a red flag at her laptop.

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ANZ shows early revenue underperformance signs, while CBA faces potential valuation corrections due to premium pricing and monetary policy pressures.
  • CSL sees a downgrade due to stalled growth, and Treasury Wine faces lowered price targets amid poor trading conditions in key markets.
  • Lendlease's divestment strategy poses near-term challenges with fewer development opportunities and ongoing struggles.

These ASX shares are on investor radars for all the wrong reasons this week. And for that reason, I'm steering clear.

Australia and New Zealand Banking Group (ASX: ANZ)

ANZ shares have stormed higher over the past 12 months, but I don't think there is any more room for the shares to run. The team at Macquarie have also flagged that the banking giant is showing early signs of revenue underperformance. It's enough for me to stay clear right now.

ANZ shares are 0.15% higher at $36.16 at the time of writing on Thursday morning.

CSL Ltd (ASX: CSL)

CSL shares have tumbled another 6% this week as investor sentiment continues to slide. On Monday, the team at Macquarie downgraded the company's shares to a neutral rating (from buy) and said the company is now out of its growth stage. The broker also heavily reduced its price target on the shares to $188, down from $275.20 previously. 

The ASX shares are trading at $173.20 a piece at the time of writing.

Treasury Wine Estates Ltd (ASX: TWE

The wine giant's shares crashed 9.29% on Wednesday after the company released an investor update and outlook for the first half of FY26. It said that trading conditions have weakened in recent months, particularly in the US and China. This means near-term improvement is unlikely. 

Macquarie analysts lowered their target price on Treasury Wine Estates shares to $5 (down from $6.40) this morning. More analyst updates on the stock are likely to come in over the next few days. I'm quietly optimistic that the latest result is mostly priced in by the market already, but I'd sit tight on the shares until the dust has settled.

At the time of writing on Thursday morning, the ASX wine giant's shares have dropped another 4.22% to $4.77 a piece.

Commonwealth Bank of Australia (ASX: CBA)

It's no secret that I'm keeping well clear of CBA shares right now. I still think the bank stock's premium share price is far too expensive, and could correct sharply from here. Discussions about tighter monetary policy and the return of rate-hike talk will continue to put pressure on the banking giant's shares, too.

At the time of writing, the ASX banking giant's shares are 0.25% lower for the day at $153.48 a piece.

Lendlease Group (ASX: LLC)

Lendlease shares have faced several headwinds this year, and according to DP Wealth Advisory's Andrew Wielandt, the company could continue to struggle in the near term. He explained that the company has reduced debt and risk by divesting overseas projects and operations, but is concerned that this may lead to fewer development opportunities because it has less capital to recycle.

At the time of writing on Thursday morning, Lendlease shares are trading at $4.95 a piece, unchanged for the day so far.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Macquarie Group and Treasury Wine Estates. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

a hand reaches out with australian banknotes of various denominations fanned out.
Dividend Investing

These 2 ASX dividend shares are great buys right now

These defensive names look like strong picks today.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

Hand holding out coal in front of a coal mine.
Energy Shares

Up 25% in 2025: Is Whitehaven Coal still a buy?

After a strong 25% run this year, investors are asking whether Whitehaven Coal still has more upside left.

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Opinions

5 ASX shares I'd buy with $10,000 this week

These are the ASX stocks I have my eye on this week.

Read more »

bull market model with a bull looking at a rising chart
Opinions

By December 2026, $1,000 invested in EOS shares could be worth…

With its share price taking off and contracts piling up, EOS is shaping up as one of the most compelling…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »